Allogene Therapeutics has been granted a patent for isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. The patent also covers methods of making and using these isolated antibodies. GlobalData’s report on Allogene Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Allogene Therapeutics, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Allogene Therapeutics's grant share as of September 2023 was 6%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is granted for isolated antibodies that bind anti-cd19 scfv
A recently granted patent (Publication Number: US11732041B2) describes an isolated antibody that specifically binds to a molecule comprising an anti-CD19 scFv. The antibody is defined by various amino acid sequences, including specific sequences for heavy chain variable regions (VH) and light chain variable regions (VL). The patent claims different combinations of these sequences, allowing for a range of antibody variations.
The isolated antibody described in the patent has a high degree of similarity to specific amino acid sequences. Claim 2 states that the VH amino acid sequence is at least 95% identical to specific sequences, while claim 3 states that the VL amino acid sequence is at least 95% identical to specific sequences. This indicates that the antibody can have slight variations in the amino acid sequences while still maintaining its specificity.
The patent also covers the isolated antibody's composition, with claim 4 specifying the amino acid sequences for the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 regions. Claims 5 and 6 provide specific combinations of VH and VL sequences, while claim 7 introduces additional VH and VL sequences.
Furthermore, the patent includes claims related to the detection and production of the isolated antibody. Claim 11 states that the antibody can include a detectable label, such as a fluorescent label or a radiolabel. Claims 13 and 14 cover the polynucleotide encoding the antibody and the vector containing the polynucleotide, respectively. Claim 15 describes a cell comprising the polynucleotide.
The patent also encompasses methods of making and using the isolated antibody. Claim 16 describes a method of making the antibody by incubating the cell containing the polynucleotide under suitable conditions. Claims 21 and 24 outline methods of determining the number of cells expressing or presenting the anti-CD19 scFv using the isolated antibody.
Overall, this granted patent provides a detailed description of an isolated antibody that specifically binds to a molecule comprising an anti-CD19 scFv. The patent covers various amino acid sequences, compositions, and methods related to the antibody's production and use.
To know more about GlobalData’s detailed insights on Allogene Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
